Dad of three daughters, Tumor Agnostic Medical Oncologist, Personalized Cancer Therapy Specialist
İstanbul, Türkiye
Joined August 2010
- Tweets1.3K
- Following522
- Followers941
- Likes1.4K
Prof.Dr.Mutlu Demiray retweeted
Imprecise fda label provides access for precision daraxonrasib therapy 🎯🔥📰👍🏻
🚨⭐️🔥 HOT OFF THE PRESS 🔥 @NatRevClinOncol
⭐️👉Pleased to share our new commentary 👉 @Dr_R_Kurzrock & I love the Daraxonrasib FDA label, and we explain why @FDA
👉 “An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval”
👉The FDA recently approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy, OR who are not candidates for multiagent systemic therapy.
👉Critics have called that second clause non-evidence-based. We see it differently.
👉Clinical trials generally enroll only patients with good performance status. That does not reflect reality for most people with metastatic pancreatic cancer. Many never reach second-line therapy because their clinical condition deteriorates first. A label written strictly around trial eligibility would leave these patients with nothing.
👉Here, the imprecision enables access. It lets physicians offer an effective RAS-targeted drug to the patients who need it most, at the point in their illness when it can still help.
👉Real-world evidence should resolve any remaining uncertainty.
👉Precision medicine should mean the right drug reaching the right patient, not a label that excludes the sickest among them @OncoAlert @oncodaily @Aiims1742 @KRASKickers @PanCAN @DianaNrco @EileenMOReilly @DrShubhamPant @GIcancerDoc
#PancreaticCancer #RAS #PrecisionOncology #FDA #OncTwitter
Link: nature.com/articles/s41571-0…
Prof.Dr.Mutlu Demiray retweeted
I miss working with you. @Papa_Heme That patient, with liver and brain mets, hospice bound, is alive in CR 11 years later. And PDL1 amp is also tumor agnostic per our paper
Remember this one, my favorite case report. nature.com/articles/npjgenme…
Prof.Dr.Mutlu Demiray retweeted
𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄: bit.ly/WINSympo2026website
𝗣𝗿𝗼𝗴𝗿𝗮𝗺 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗖𝗼𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗚𝗿𝗼𝘂𝗽 𝘄𝗶𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 (𝗔𝗖𝗦) 𝗣𝗮𝗻𝗲𝗹
At 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲, this panel will bring together leaders from cooperative groups, cancer research and oncology organizations to explore collaboration across the cancer research ecosystem.
Co-Chair:
𝗗𝗿. 𝗚𝗲𝘃𝗼𝗿𝗴 𝗧𝗮𝗺𝗮𝗺𝘆𝗮𝗻, 𝗠𝗗, 𝗠𝗦𝗰, 𝗣𝗵𝗗
Oncodaily, USA
Panelists include:
𝗗𝗿. 𝗣𝗲𝘁𝗲𝗿 𝗝. 𝗢’𝗗𝘄𝘆𝗲𝗿, 𝗠𝗗
Group Co-Chair, ECOG-ACRIN Cancer Research Group, Perelman School of Medicine, University of Pennsylvania, USA
𝗗𝗿. 𝗣𝗮𝘂𝗹 𝗖𝗮𝗺𝗽𝗯𝗲𝗹𝗹, 𝗣𝗵𝗗
American Cancer Society (ACS), USA
𝗗𝗿. 𝗘𝗹𝘃𝗮𝗻 𝗗𝗮𝗻𝗶𝗲𝗹𝘀, 𝗠𝗗, 𝗠𝗣𝗛
American Cancer Society (ACS), USA
𝗗𝗿. 𝗖𝗵𝗮𝗿𝗹𝗲𝘀 𝗕𝗮𝗹𝗰𝗵, 𝗠𝗗, 𝗙𝗔𝗦𝗖𝗢, 𝗙𝗔𝗖𝗦
International Society of Oncology Prevention and Treatments (ISOPT), Houston, TX, USA
𝗗𝗿. 𝗥𝗮𝘇𝗲𝗹𝗹𝗲 𝗞𝘂𝗿𝘇𝗿𝗼𝗰𝗸, 𝗠𝗗, 𝗙𝗔𝗖𝗣
Chair and Board of Governors Member, USA
𝗗𝗿. 𝗜𝗹𝘆𝗮𝘀 𝗦𝗮𝗵𝗶𝗻, 𝗠𝗗
Massachusetts General Hospital, USA
𝗗𝗿. 𝗦𝘁𝗲𝗽𝗵𝗲𝗻 𝗚. 𝗖𝗵𝘂𝗻, 𝗠𝗗
NRG Oncology Group, USA
𝗗𝗿. 𝗪𝗮𝗳𝗶𝗸 𝗘𝗹-𝗗𝗲𝗶𝗿𝘆, 𝗠𝗗, 𝗣𝗵𝗗, 𝗙𝗔𝗖𝗣
Chair of the WIN Consortium, Symposium Director, USA
𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 takes place 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮-𝟯, 𝟮𝟬𝟮𝟲 𝗮𝘁 𝘁𝗵𝗲 𝗥𝗵𝗼𝗱𝗲 𝗜𝘀𝗹𝗮𝗻𝗱 𝗖𝗼𝗻𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗖𝗲𝗻𝘁𝗲𝗿 𝗶𝗻 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗥𝗵𝗼𝗱𝗲 𝗜𝘀𝗹𝗮𝗻𝗱, 𝗨𝗦𝗔.
𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 is endorsed by the American Society of Clinical Oncology (ASCO®).
Register now to join the discussion.
#WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #ClinicalResearch
ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.
Prof.Dr.Mutlu Demiray retweeted
🤩🔥🔥🤩
Excited and looking forward to the 2026 WIN Symposium in Providence, Rhode Island, October 2-3, 2026.
Register and submit an abstract (deadline September 17, 2026). mcigroup-winsymposium2026.ev…
Registration fees waived for students and trainees who submit abstracts to this meeting. Accepted abstracts will be included in the program book. Remember the extended deadline is September 17 for abstract submissions.
There is still time for our pharma colleagues to register and attend this meeting for learning, networking opportunities, and global impact in precision oncology.
See you in Rhode Island in October at this amazing conference.
@WIN_Consortium @Dr_R_Kurzrock @LussierY @LiaTsimberidou @DrRoyHerbst @SewantiLimaye @LiangChengMD @bcarneiro7 @VivekSubbiah @billdahutmd @jrgralow @ASCO @AACRPres @realrickpazdur @curijoey @CancerConnector @AmericanCancer @SeanLawler20 @DawsonStemCell @ianywonglab @DrMartyTaylor @MiaForRep @JoeShekarchi @RepGabeAmo @SenJackReed @BrownUniversity @BrownUnivHealth @oncodaily @Oncotarget @OncoAlert @oncologytube @VJHemOnc
Prof.Dr.Mutlu Demiray retweeted
The FDA 🇺🇸granted accelerated approval to camizestrant, combined with a CDK4/6 inhibitor, for HR-positive, 🧬HER2-negative advanced #BreastCancer patients who develop ESR1 mutations during aromatase inhibitor and CDK4/6 inhibitor therapy.
fda.gov/news-events/press-an…
@hoperugo
@JavierCortesMD
@FAndreMD
@matteolambe
@ErikaHamilton9
@DrSGraff
@aftimosp
@BianchiniGP
@ElisaAgostinett
@raalbany
@jamecancerdoc
@Icro_Meattini
@stolaney1
@maryam_lustberg
@LoiSher
@stage4kelly
@to_be_elizabeth
@RebeccaDSing
@double_whammied
@itsnot_pink
@coffeemommy
@FernandoOnco
@JaniceTNBCmets
@TanjaSpanic
@christeeny513
@stage4kelly
@Prof_Nadia_H
@E_de_Azambuja
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@UOzkerim
@DrVilmaPBarcia
@nataliagandur
Prof.Dr.Mutlu Demiray retweeted
Co-targeting drivers. The I-PREDICT model
🚨⭐️Sharing for your Sunday morning read 👉🏼Beyond one gene, one target: Next-generation precision oncology: Trends in Cancer @trendscancer @Dr_R_Kurzrock @OncoAlert @oncodaily
cell.com/trends/cancer/fullt…
Prof.Dr.Mutlu Demiray retweeted
New @NatRevClinOncol led by @AshleyEadie @PrelajArsela Andrea Villa: the biggest near-term value of AI in #oncology trials is getting more patients onto the RIGHT trials faster. We summarize the state of the science. #AI #Oncology
New online! AI-based augmentation of oncology clinical trials dlvr.it/TTvW71
Prof.Dr.Mutlu Demiray retweeted
Pleased to share the latest publication by the @WIN_Consortium
Worldwide Innovative Network Consortium: Building a Common Global Cancer Database
“WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence–driven insights, provided appropriate data quality, validation, and governance frameworks are in place”
ascopubs.org/doi/10.1200/GO-…
@LussierY @Dr_R_Kurzrock @Jens_Reuter @SewantiLimaye @alshamsi2000 @drKMusallam @DrRoyHerbst @LiangChengMD @LiaTsimberidou @jrgralow @billdahutmd @SWOG @theNCI @ASCO @AACR
Prof.Dr.Mutlu Demiray retweeted
Haftayı güzel bir haberle kapatalım.
Atelier Wen bundan böyle Turkish Watch Guy’da.
@UnluDoruk
Prof.Dr.Mutlu Demiray retweeted
Razelle Kurzrock Shares Perspectives on Precision Oncology and Rare Cancers
@Dr_R_Kurzrock
oncodaily.com/voices/razelle…
Prof.Dr.Mutlu Demiray retweeted
This is precision medicine given at diagnosis, not after standard of care fails, when it doesn’t work well. The hematologists understood this principle.
Doctors gave me three years.
A clinical trial gave me thirty-one and counting.
I was 37, terminal CML, no bone marrow match. Gleevec was still experimental. I said yes to the trial because it was my only real shot at tomorrow’s medicine today.
That decision let me watch my daughter grow up and become a doctor. It let me keep living.
Clinical trials aren’t a last resort. They’re often the first real chance at more time.
If you’re facing a diagnosis, ask about them. Your story could be the next one that rewrites the odds.
#ClinicalTrials #CML #Gleevec #PatientAdvocate
Prof.Dr.Mutlu Demiray retweeted
𝗩𝗶𝗲𝘄 𝘁𝗵𝗲 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗮𝗻𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿: bit.ly/WINSympo2026website
𝗡𝗲𝘄 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗮𝗻𝗱 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝗳𝗼𝗿 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲.
𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 is endorsed by 𝗔𝗦𝗖𝗢®, supporting the scientific positioning of this year’s program.
Taking place 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮-𝟯, 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗥𝗵𝗼𝗱𝗲 𝗜𝘀𝗹𝗮𝗻𝗱, 𝗨𝗦𝗔, WIN Symposium 2026 will bring together an international faculty of leaders across oncology, precision medicine, translational science, AI and data science, radiation oncology, rare cancers, global collaboration, and clinical implementation.
This year’s program will explore:
𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗘𝗾𝘂𝗶𝘁𝘆 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗚𝗹𝗼𝗯𝗲
New speaker highlights include:
𝗗𝗿. 𝗩𝗶𝘃𝗲𝗸 𝗦𝘂𝗯𝗯𝗶𝗮𝗵, 𝗠𝗗 - Keynote speaker, with a focus on precision oncology in practice, including early detection, rare and complex cancers, and tumor-agnostic approaches
𝗗𝗿. 𝗖𝗵𝗮𝗿𝗹𝗲𝘀 𝗕𝗮𝗹𝗰𝗵, 𝗠𝗗 - Global precision oncology, access, equity, and international collaboration
𝗗𝗿. 𝗬𝘃𝗲𝘀 𝗟𝘂𝘀𝘀𝗶𝗲𝗿, 𝗠𝗗 - Artificial intelligence and data science in precision oncology
𝗗𝗿. 𝗕𝗲𝗻𝗲𝗱𝗶𝘁𝗼 𝗔. 𝗖𝗮𝗿𝗻𝗲𝗶𝗿𝗼, 𝗠𝗗, 𝗠𝗦 - Translational oncology
𝗗𝗿. 𝗗𝗮𝘃𝗶𝗱 𝗦𝗽𝗲𝘁𝘇𝗹𝗲𝗿, 𝗠𝗗 - AI, genomic profiling, and the changing frontier of precision medicine
𝗗𝗿. 𝗦𝘁𝗲𝗽𝗵𝗲𝗻 𝗖𝗵𝘂𝗻, 𝗠𝗗 - Radiation oncology and checkpoint immunotherapy
𝗗𝗿. 𝗝𝗮𝗰𝗼𝗯 𝗦𝗰𝗼𝘁𝘁, 𝗠𝗗 - Personalized medicine in radiation oncology
𝗗𝗿. 𝗘𝘆𝘁𝗮𝗻 𝗥𝘂𝗽𝗽𝗶𝗻, 𝗠𝗗, 𝗣𝗵𝗗 - Fast and accessible precision oncology
𝗗𝗿. 𝗕𝗶𝗰𝗸𝘆 𝗧𝗵𝗮𝗽𝗮, 𝗠𝗗 - Rare genitourinary cancers in the precision era
Join the international precision oncology community in Providence for two days of scientific exchange, collaboration, and discussion.
*@ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.
#WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #TranslationalResearch
Prof.Dr.Mutlu Demiray retweeted
Bir hekimin mal varlığına konulan haciz, yalnızca bir dosyanın konusu değildir. Bazen yarının ameliyathanelerine vurulan görünmez bir kilittir.
tibbiyebulteni.com/cerrahlar… @tibbiyebulteni
🤖 Made with AI
Prof.Dr.Mutlu Demiray retweeted
The #𝗪𝗜𝗡𝗦𝘆𝗺𝗽𝗼𝟮𝟲 event website is now live 🌐
Registration & poster abstract submission are now open for #𝗪𝗜𝗡𝗦𝘆𝗺𝗽𝗼𝟮𝟲, taking place on 2–3 October 2026 in Providence, Rhode Island, USA.
🔗 mcigroup-winsymposium2026.ev…
Prof.Dr.Mutlu Demiray retweeted
“Same trial. Two regulators. Two completely different conclusions.”
Why did the US FDA Oncologic Drugs Advisory Committee (ODAC) hesitate… while the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) moved toward approval?
This isn’t just about camizestrant.
It’s about a much bigger question in oncology:
👉 Should we act when molecular resistance appears?
OR
👉 Wait until radiologic progression becomes visible?
🇺🇸 FDA/ODAC: “Is the evidence mature enough?”
🇪🇺 EMA/CHMP: “Why wait for scans to worsen?”
SERENA-6 may become a defining moment for ctDNA-guided precision oncology.
#BreastCancer #SERENA6 #Camizestrant #ctDNA #PrecisionOncology #ESR1 #Oncology #MedEd #MVOnco
Prof.Dr.Mutlu Demiray retweeted
HER2 isn’t binary — it’s a continuum.
Quantitative HER2 levels correlate with activity of trastuzumab deruxtecan, highlighting the limitations of traditional IHC categories.
Perhaps the future of HER2 testing is measurement, not classification.
#MVOnco #BreastCancer #ADC
Prof.Dr.Mutlu Demiray retweeted
Don’t we need a randomized study? Correlation is not causation
In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P
Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors nej.md/3N0pQW8
ALT Panel A: A figure showing the change in the sum of diameters of the target lesions across tumor types. Panel B: A figure showing the overall duration of treatment and the time to first response observed in 46 patients treated with a dose in the observed efficacious-dose range who had wild-type KRAS.
Prof.Dr.Mutlu Demiray retweeted
Thanks @UroDocAsh on your leadership of @IBCG_BladderCA to develop this consensus on optimal management of MIBC.
Honored to be part of this 🌎 multi-D panel of colleagues and patient advocates to provide practical guidance for point-of-care decision-making and modern trial designs in MIBC.
@WorldBladderCan @BladderCancerUS @PGrivasMDPhD @mouwlab @siadaneshmand @AndreaNecchi @PGrivasMDPhD @UrogerliMD @pjhensley11 @karima_oualla @FaltasLab @carme_mir1 @DrRosenbergMSK @AStenzl @JoshMeeks
@OncoAlert @Uroweb @neerajaiims @montypal
New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)
Full text: authors.elsevier.com/a/1mf5C…
@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
Prof.Dr.Mutlu Demiray retweeted
Bu videoyu izleyin, tüm sevdiklerinize gönderin ve izletin ve videoda söylenenleri HARFİYEN uygulayın. Herkese Sevgiler ❤️
Prof.Dr.Mutlu Demiray retweeted
Our commentary. Very important
🚨⭐️Sharing our comment just published @TheLancetOncol @TheLancet "Factors that can make overall survival unreliable as a clinical trial outcome" - The Lancet Oncology @OncoAlert @oncodaily @Dr_R_Kurzrock
thelancet.com/journals/lanon…